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When type III interferon (IFN-l; also known as interleukin-28 [IL-28] and IL-29) was discovered in 2003, its
antiviral function was expected to be analogous to that of type I IFNs (IFN-a and IFN-b) via the induction
of IFN-stimulated genes (ISGs). Although IFN-l stimulates expression of antiviral ISGs preferentially in cells
of epithelial origin, recent studies have defined additional antiviral mechanisms in other cell types and tis-
sues. Viral infection models using mice lacking IFN-l signaling and SNP associations with human disease
have expanded our understanding of the contribution of IFN-l to the antiviral response at anatomic barriers
and the immune response beyond these barriers. In this review, we highlight recent insights into IFN-l func-
tions, including its ability to restrict virus spread into the brain and to clear chronic viral infections in the
gastrointestinal tract. We also discuss how IFN-l modulates innate and adaptive immunity, autoimmunity,
and tumor progression and its possible therapeutic applications in human disease.Introduction
Interferon-l (IFN-l), also termed type III IFN or interleukin-28
(IL-28) and IL-29, belongs to a cytokine family that shares func-
tional similarities with the family of type I IFNs (IFN-a and/or
IFN-b [hereafter IFN-a/b]). IFN-l and IFN-a/b aremulti-gene fam-
ilies composed of closely related cytokines each with specific
heterodimeric receptors: IFNLR (IFNLR1 and IL10Rb) for IFN-l
and IFNAR (IFNAR1 and IFNAR2) for IFN-a/b. Humans have
genes encoding four IFN-l proteins (IFN-l1 [IL-29], IFN-l2
[IL-28A], IFN-l3 [IL-28B], and IFN-l4) as well as 17 IFN-a/b pro-
teins (13 IFN-a subtypes, IFN-b, IFN-u, IFN-ε, and IFN-k). In
contrast to the IFN-a/b family, which was described almost
60 years ago (Isaacs and Lindenmann, 1957), the IFN-l family
was discovered more recently. Human IFN-l1, IFN-l2, and
IFN-l3 were identified in 2003 (Kotenko et al., 2003; Sheppard
et al., 2003), and IFNL4 at that time was considered a pseudo-
gene. In 2013, it became clear that many humans have a func-
tional IFNL4 and that a common SNP results in a frameshift
mutation that ablates IFN-l4 production in some populations
(Hamming et al., 2013; Prokunina-Olsson et al., 2013). Genes
encoding type I IFNs characteristically lack introns (with the
exception of IFNK) and are syntenic in a single locus on human
chromosome 9 and mouse chromosome 4. Genes encoding
IFN-l are located on human chromosome 19 and mouse chro-
mosome 7 and share the 5-exon gene structure characteristic
of IL-10 cytokine family members (Sabat, 2010).
As discussed herein and in other recent reviews (Donnelly and
Kotenko, 2010; Durbin et al., 2013; Egli et al., 2014c; Griffiths
et al., 2015; Hermant and Michiels, 2014; Hoffmann et al.,
2015; Koch and Finotto, 2015; Kotenko, 2011; O’Brien et al.,2014; Odendall and Kagan, 2015), several aspects of IFN-l
biology differ from IFN-a/b biology. First, the effects of IFN-l
are most evident in epithelial cells, suggesting that it contributes
to the specialized immune mechanisms that protect epithelial
surfaces, which undergo constant exposure to commensal and
pathogenic microbes (Durbin et al., 2013; Hermant and Michiels,
2014; Mahlako˜iv et al., 2015). Second, because of the more
focused nature of its signaling effects, IFN-l might share the
therapeutic benefits yet avoid many of the side effects that
have limited the clinical use of IFN-a/b (Donnelly et al., 2011;
Hermant and Michiels, 2014; Markowitz, 2007; Pagliaccetti and
Robek, 2010; Pestka, 2007). Third, genome-wide association
studies (GWASs) have revealed multiple IFNL polymorphisms
that are linked to clearance of hepatitis C virus (HCV) infection
and possibly improved outcomes with other viral infections,
including hepatitis B virus (HBV), human cytomegalovirus
(HCMV), and herpes simplex virus 1 (HSV-1) (Egli et al., 2014c;
Galmozzi et al., 2014; Griffiths et al., 2015; Lampertico et al.,
2013; Manuel et al., 2015).
In this review, we discuss new insights into the antiviral func-
tions of IFN-l, especially those distinguishing it from IFN-a/b.
We also describe how IFN-lmodulates adaptive immunity, auto-
immunity, and tumor progression, as well as possible therapeu-
tic applications in human disease. We highlight a specialized role
for IFN-l in providing antiviral activity at anatomic barriers,
including epithelial surfaces and the blood-brain barrier (BBB).
Because epithelial surfaces experience constant microbial
exposure, IFN-lmight provide more targeted antiviral protection
at key barrier sites without activating a systemic pro-inflamma-
tory immune response.Immunity 43, July 21, 2015 ª2015 Elsevier Inc. 15
Figure 1. IFN-l Induction and Signaling
Pathways
IFN-l production is induced when viral infection is
sensed by pattern recognition receptors (PRRs),
including members of the RIG-I-like receptor (RLR)
and Toll-like receptor (TLR) families, as well as the
DNA sensor Ku70. Whereas IFN-l is induced via
many of the same signaling pathways that induce
IFN-a/b, Ku70 and peroxisome-localized MAVS
preferentially induce IFN-l. IFN-l signals through
its heterodimeric receptor, IFNLR, which is
composed of IFNLR1 and IL10Rb subunits. Ca-
nonical signaling through IFNLR activates JAK1
and TYK2 kinases, which phosphorylate STAT1
and STAT2. However, IFNLR signaling also can
activate JAK2 and other downstream signaling
pathways (not depicted). JAK-STAT signaling in-
duces expression of IFN-stimulated genes (ISGs)
and the production of effector molecules that
inhibit viral infection. Among the ISGs induced by
IFN-l are IRF1 and IRF7, encoding transcription
factors IRF-1 and IRF-7, respectively, which
amplify IFN production.
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Distinct from Those of IFN-a/b
The stimuli that induce expression of IFN-l-encoding genes,
including a range of viruses, are similar to those inducing expres-
sion of genes encoding IFN-a/b (Ank et al., 2008; Ank et al., 2006;
Durbin et al., 2013; Kotenko et al., 2003; Sheppard et al., 2003).
Nonetheless, there are differences in transcription factor require-
ments between IFN-a/b and IFN-l. Given that some of these dif-
ferences have been reviewed previously (Durbin et al., 2013;
Iversen and Paludan, 2010), we highlight recent advances in
our understanding of transcriptional regulation of IFN-l-encod-
ing genes.
IFN expression occurs after host detection of pathogen-asso-
ciated molecular patterns by specific pattern-recognition recep-
tors (PRRs) (Swiecki and Colonna, 2011; Figure 1). Although
most PRRs responsible for inducing expression of IFN-l overlap
those triggering IFN-a/b expression, the cytosolic DNA sensor
Ku70 activates the expression of IFN-l but not IFN-a/b (Zhang
et al., 2011). Transcription factors activated downstream of
PRR signaling include interferon regulatory factors (IRFs) and
NF-kB. The suite of PRRs and transcription factors expressed
by a cell contributes to the specific capabilities and magnitude
of the IFN response following infection (Hillyer et al., 2012). For
example, IFN-b is induced early after activation of PRRs because
its promoter is bound by IRF-3, which is constitutively ex-
pressed, whereas most IFN-a subtypes are induced preferen-
tially by IRF-7, which is itself encoded by an IFN-stimulated
gene (ISG) (Ge´nin et al., 2009). Initial characterization of pro-
moter regions upstream of IFNL1 and IFNL3 identified binding
elements for IRF-1, IRF-3, IRF-7, and NF-kB, and the combined
activity of IRFs and NF-kBwas required for maximal gene induc-
tion (Onoguchi et al., 2007; Osterlund et al., 2007; Thomson
et al., 2009). Subsequent analysis of the response to TLR9 ago-
nists showed that IFN-l induction exhibits a greater dependence
on NF-kB than does IFN-a/b induction (Iversen et al., 2010).
These findings suggest that, despite similarities, there are pro-
moter features that discriminate IFNL and IFNA/B induction.16 Immunity 43, July 21, 2015 ª2015 Elsevier Inc.Additional factorsdistinguish the regulation of IFNLand IFNA/B
induction. Med23, a component of the Mediator complex, inter-
acts with IRF-7 and enhances transcription from the IFNL1 pro-
moter, but not the IFNB promoter; the resulting increase in
IFN-l production inhibits HSV-1 replication (Griffiths et al.,
2013). A bioinformatic and biochemical analysis of the region up-
stream of human IFNL1 identified binding sites for the transcrip-
tion factors ZEB1 and BLIMP-1. Experiments using chromatin
immunoprecipitation and gene silencing established that ZEB1
and BLIMP-1 bind the IFNL1 promoter and repress transcription
in airway and intestinal epithelial cell lines (Siegel et al., 2011;
Swider et al., 2014). ZEB1 activity is specific to IFNL1 and does
not regulate IFNB expression. BLIMP-1 functions as a repressor
by displacing binding of IRF-1 (Siegel et al., 2011), which is
required for IFNL1, but not IFNB, transcription (Odendall et al.,
2014). Although both IFN-l and IFN-b are induced downstream
of PRR sensing and activation of mitochondrial antiviral signaling
protein (MAVS), IFN-l production is favored when activated
MAVS localizes to the peroxisome, whereas IFN-b production is
dominant when MAVS localizes to the mitochondria (Odendall
et al., 2014). The relative abundance of peroxisomes in epithelial
cells suggests a mechanism for preferential production of IFN-l
insteadof IFN-b in response toviral infectionat epithelial surfaces.
In hepatocytes, HBV infection stimulated production of IFN-l but
not IFN-a/b, and this IFN-l induction depended on recognition by
RIG-I and signaling through MAVS (Sato et al., 2015). Similarly,
HCV infection preferentially induced IFN-l over IFN-a/b (Maru-
kianet al., 2011;Parket al., 2012;Thomasetal., 2012), suggesting
that liver-specific factors might promote IFN-l production in
response to these unrelated hepatotropic viruses.
Although epithelial cells produce IFN-l, myeloid-lineage cells
are major sources in response to double-stranded RNA (poly
I:C) or viral infections (Lauterbach et al., 2010). In the small intes-
tine, epithelial cells and immune cells both respond to poly I:C
stimulation, suggesting that multiple cell types produce IFN-l
cooperatively (Mahlako˜iv et al., 2015). Although gut immune cells
treated with poly I:C produce IFN-a5, IFN-b, IFN-l2, and IFN-l3,
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lako˜iv et al., 2015), perhaps reflecting their peroxisome content
(Odendall et al., 2014). There also are differences in the IFN in-
duction profile within the myeloid cell compartment after stimu-
lation with PRR agonists. Whereas plasmacytoid dendritic cells
(DCs) produce nearly all IFNs (including IFN-l), monocytes and
myeloid DCs more selectively express IFN-b, IFN-l1, and IFN-
l2 (Hillyer et al., 2012). Similarly, CD8a+ DCs are the major
IFN-l-producing myeloid cell type in response to poly I:C in
mice (Lauterbach et al., 2010).
IFN-l Signaling
The proximal signaling events and downstream transcriptional
responses are similar between IFN-a/b and IFN-l, even though
the cytokines and their receptors are structurally and genetically
distinct. The structure of IFN-l resembles that of members of the
IL-10 family, although the primary amino acid sequence is more
similar to that of IFN-a/b (Gad et al., 2009; Miknis et al., 2010).
Whereas all type I IFNs signal through a shared heterodimeric re-
ceptor, IFNAR (IFNAR1 and IFNAR2), type III IFNs bind to IFNLR,
a unique heterodimeric receptor. IFNLR consists of one subunit
that it shares with other IL-10 family cytokines (IL10Rb) and a
second that is specific to IFN-l (IFNLR1, also called IL28Ra).
Despite the structural similarities between IFN-l and IL-10 family
cytokines (i.e., IL-10, IL-19, IL-20, IL-22, IL-24, and IL-26), the
crystal structure of IFN-l1 bound to IFNLR1 revealed a distinct
receptor-binding interaction, including a 1:1 stoichiometry be-
tween IFN-l1 and IFNLR1 (compared to 2:1 between IL-10 and
IL10Ra) (Miknis et al., 2010). The impact of the shared IL10Rb
chain on interactions between IFN-l and other IL-10 family cyto-
kines remains unclear. IFN-l activity was enhanced by an IL-10-
blocking antibody and was inhibited in the presence of IL-10
(Jordan et al., 2007a), suggesting possible competition for
IL10Rb interaction. In contrast, IL-22 (which signals through
IL10Rb and IL22Ra) enhanced the signaling and antiviral effects
of IFN-l (Herna´ndez et al., 2015). Although IFNAR and IL10Rb
are expressed broadly on many cell types and tissues, IFNLR1
is expressed preferentially on epithelial cells (Mahlako˜iv et al.,
2015; Sommereyns et al., 2008). Consistent with this pattern,
the antiviral effects of IFN-l are most evident against pathogens
targeting epithelial tissues.
Despite engaging different heterodimeric receptors, the post-
receptor signaling events after IFN-a/b and IFN-l binding exhibit
remarkable overlap. These signaling pathways have been re-
viewed in detail elsewhere (Donnelly and Kotenko, 2010; Durbin
et al., 2013; Hoffmann et al., 2015; Kotenko, 2011) and include
activation of JAK-family kinases, phosphorylation of STAT1
and STAT2, and association between activated STAT com-
plexes and IRF-9 to form ISGF3, which translocates to the nu-
cleus and induces expression of hundreds of ISGs. Similar to
IFN-a/b signaling, IFN-l signaling induces JAK1 and TYK2 phos-
phorylation (Dumoutier et al., 2004; Franc¸ois-Newton et al.,
2011; Ma et al., 2009). Additionally, JAK2 phosphorylation is
induced specifically by IFN-l (Odendall et al., 2014; Odendall
and Kagan, 2015), suggesting that distinct upstream signaling
events might differentiate IFN-l activity from IFN-a/b activity.
In addition to activating STAT1 and STAT2, IFNAR and IFNLR
ligand engagement can activate other STAT family members
(STAT3, STAT4, and STAT5) and STAT-independent signalingcascades (MAPK and ERK) (Cohen and Prince, 2013; Koch
and Finotto, 2015).
The transcriptional responses induced by IFN-l and IFN-a/b
are similar (Bolen et al., 2014; Doyle et al., 2006; Kohli et al.,
2012; Lazear et al., 2015; Marcello et al., 2006; Shindo et al.,
2013; Zhou et al., 2007). No transcriptional signatures unique
to IFN-l have been identified, and the genes induced by IFN-l
typically represent a subset of the total induced by IFN-a/b.
The IFN-l transcriptional response generally is of lower magni-
tude than that of IFN-a/b and might exhibit a delayed peak and
longer duration (Marcello et al., 2006), although different expres-
sion levels of IFNAR and IFNLR might confound comparisons.
Differential effects of negative regulators might contribute to
the sustained signaling pattern observed for IFN-l in comparison
to that of IFN-a. For example, the ISG USP18 desensitizes cells
to further IFN-a stimulation but does not inhibit IFN-l signaling
(Franc¸ois-Newton et al., 2011). Among the IFN-l subtypes,
IFN-l3 (followed by IFN-l1 and IFN-l2) has the most potent
bioactivity (Bolen et al., 2014; Dellgren et al., 2009). These differ-
ences in potency are unexpected, given that IFN-l2 and IFN-l3
are nearly identical (96% amino acid identity) (Sheppard et al.,
2003). IFN-a/b and IFN-l signaling both amplify IFN production,
for example, via the induction of the transcription factors IRF-1
and IRF-7 (Bolen et al., 2014; Kohli et al., 2012; Lazear et al.,
2015). Because of these shared positive-feedback systems,
transcriptional profiling in cells lacking IFNAR or IFNLR (or in
the presence of protein-synthesis inhibitors) might be needed
for distinguishing bona fide IFN-a/b- and IFN-l-induced genes.
Independent of whether there truly are IFN-l-specific transcrip-
tional signatures, the ability to induce a narrower set of ISGs in a
more targeted set of cells suggests possible therapeutic applica-
tions in which IFN-l could promote a more focused antiviral or
immunomodulatory response with fewer side effects than IFN-
a/b (Hermant and Michiels, 2014; Muir et al., 2014). Given that
most IFN-l transcriptional profiling experiments have focused
on human liver cells, further studies are needed in other tissues
where antiviral effects of IFN-l have been reported.
Antiviral Effects of IFN-l
IFN-l exhibits antiviral activity against many viruses in vitro, but
its in vivo activity has been more apparent for viruses that infect
epithelial cells of the respiratory, gastrointestinal, and urogenital
tracts, as well as the liver (Table 1). Because the antiviral effects
of IFN-l have been reviewed recently (Egli et al., 2014c; Hermant
and Michiels, 2014; O’Brien et al., 2014; Sorgeloos et al., 2013),
we will briefly describe the role of IFN-l in the respiratory tract
and liver and then highlight new phenotypes in the gastrointes-
tinal tract, as well as at an unexpected site, the BBB.
IFN-l in the Respiratory Tract
IFNLR is expressed at relatively high levels in respiratory epithe-
lial cells, and mice treated with IFN-l prior to infection with hu-
man metapneumovirus (HMPV) develop lower viral titers and
reduced inflammatory responses (Ban˜os-Lara et al., 2015).
Accordingly, Ifnlr1/ mice exhibit increased susceptibility to
respiratory viral infections, including influenza virus, HMPV, res-
piratory syncytial virus, and SARS coronavirus (Crotta et al.,
2013; Hermant andMichiels, 2014; Mahlako˜iv et al., 2012; Mord-
stein et al., 2008; Mordstein et al., 2010b). Human myeloid and
bronchial epithelial cells produce IFN-l in response to rhinovirusImmunity 43, July 21, 2015 ª2015 Elsevier Inc. 17
Table 1. Antiviral Effects of IFN-l In Vivo
Virus Phenotype Reference
Mouse Models
West Nile virus more permeable BBB and increased
neuroinvasion in Ifnlr1/ mice; treatment
with recombinant IFN-l prevents lethality in
wild-type mice
Lazear et al., 2015
Norovirus increased titers and shedding in Ifnlr1/ mice;
treatment with recombinant IFN-l prevents
infection and cures persistent infection
Nice et al., 2015
Reovirus increased growth in intestinal epithelial cells
and increased viral shedding in Ifnlr1/ mice;
increased fatal liver disease in suckling Ifnlr1/
mice
Mahlako˜iv et al., 2015
Rotavirus increased titers in Ifnlr1/mice; treatment with
recombinant IFN-l reduces viral titers; IL-22
acts synergistically with IFN-l to control
infection
Herna´ndez et al., 2015; Pott et al., 2011
Influenza virus increased titers in Ifnlr1/ or Ifnlr1/ 3
Ifnar1/ mice; treatment with recombinant
IFN-l prevents lethality in wild-type mice
Crotta et al., 2013; Mordstein et al., 2008;
Mordstein et al., 2010b
SARS coronavirus increased titers and shedding in Ifnlr1/ mice Mahlako˜iv et al., 2012; Mordstein et al., 2010b
Human metapneumovirus increased titers in Ifnlr1/ 3 Ifnar1/ mice;
treatment with recombinant IFN-l reduces
titers in wild-type mice
Ban˜os-Lara et al., 2015; Mordstein et al., 2010b
Respiratory syncytial virus increased titers in Ifnlr1/ 3 Ifnar1/ mice Mordstein et al., 2010b
Herpes simplex virus 2 treatment with recombinant IFN-l decreases
viral titers and shedding
Ank et al., 2006
Lymphocytic choriomeningitis virus no change in viral titers in Ifnlr1/ mice;
increased T cell response to acute infection and
decreased T cell response to chronic infection
in Ifnlr1/ mice
Ank et al., 2008; Misumi and Whitmire, 2014
Human Patients
Hepatitis C virus SNPs rs8099917, rs12979860, rs4803217, and
rs368234815 correlate with spontaneous
clearance and sustained response to IFN
therapy
Bibert et al., 2013; Ge et al., 2009; Griffiths
et al., 2015; Hamming et al., 2013; Prokunina-
Olsson et al., 2013; Suppiah et al., 2009;
Tanaka et al., 2009; Thomas et al., 2009
Hepatitis B virus SNP rs12979860 correlates with response to
IFN therapy
Galmozzi et al., 2014
Human cytomegalovirus SNP rs368234815 correlates with HCMV
retinitis in AIDS patients; SNPs rs368234815
and rs8099917 correlate with HCMV
reactivation in transplant recipients
Bibert et al., 2014; Egli et al., 2014a; Egli et al.,
2014c; Griffiths et al., 2015; Manuel et al., 2015
Herpes simplex virus 1 SNP rs12979860 correlates with the severity of
reactivation disease
Griffiths et al., 2013
Influenza virus increased viral titers in epithelial cells with
IFNLR1 inhibition; SNP rs8099917 correlates
with vaccine response in immunosuppressed
patients
Egli et al., 2014b; Kim et al., 2013
Rhinovirus increased production of IFN-l correlates with
reduced viral replication in bronchial epithelial
cells
Contoli et al., 2006
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epithelial cells (Contoli et al., 2006). Correspondingly, production
of IFN-l correlates inversely with viral load and disease severity
in humans experimentally inoculated with rhinovirus (Contoli
et al., 2006). Respiratory epithelial cells respond to both IFN-l18 Immunity 43, July 21, 2015 ª2015 Elsevier Inc.and IFN-a/b (Mahlako˜iv et al., 2015), and cultured cells respond
to IFN-l from both the apical and basolateral surfaces (Fox et al.,
2015; Hamming et al., 2013). IFN-l is the dominant IFN produced
by respiratory epithelial cells after infection with influenza virus or
other respiratory viruses (Crotta et al., 2013; Fox et al., 2015;
Immunity
ReviewJewell et al., 2010; Okabayashi et al., 2011). This implies a key
role for IFN-l in mediating antiviral immunity in the respiratory
tract (Figure 2A).
IFN-l in the Liver
There has been great interest in defining the antiviral role of IFN-l
in the liver, particularly against HCV and HBV infections. IFNLR is
expressed by human hepatocytes, the primary cellular targets of
these viruses (Figure 2B), and both viruses preferentially stimu-
late IFN-l production rather than IFN-a/b production (Marukian
et al., 2011; Park et al., 2012; Sato et al., 2015; Thomas et al.,
2012). GWASs have revealed IFNL polymorphisms that are asso-
ciated with improved outcome from HCV and HBV infection,
both in terms of spontaneous clearance and in response to anti-
viral therapy (Galmozzi et al., 2014; Ge et al., 2009; Griffiths et al.,
2015; Hermant and Michiels, 2014; Lampertico et al., 2013;
O’Brien et al., 2014; Russell et al., 2014; Suppiah et al., 2009; Ta-
naka et al., 2009; Thomas et al., 2009). The different protective
alleles identified in these studies imply distinct antiviral mecha-
nisms against HCV. One protective allele in the promoter region
of IFNL3 is associated with increased IFN-l production, which
might control infection by enhancing expression of ISGs (for
SNP rs8099917, the protective allele is T/T rather than T/G or
G/G) (Suppiah et al., 2009; Tanaka et al., 2009). However, an un-
favorable allele also is associated with elevated ISG expression
and is thought to render cells refractory to further stimulation of
antiviral activity (for SNP rs12979860, the protective allele is C/C
rather than T/C or T/T) (Ge et al., 2009; Sheahan et al., 2014;
Thomas et al., 2009; Urban et al., 2010). In addition to its associ-
ation with viral hepatitis, rs12979860 predicts the severity of liver
inflammation and fibrosis of other etiologies, but with the oppo-
site association (C/C, unfavorable allele) (Eslam et al., 2015). This
disparity suggests that ISG expression might differentially affect
viral and non-viral liver disease. Another protective allele alters
the sequence of the 30 UTR of IFNL3 such that its transcript is
no longer targeted for degradation by microRNAs induced after
HCV infection (for SNP rs4803217, the protective allele is G/G
rather than T/T) (McFarland et al., 2014). The SNP that is most
highly associated with improved HCV outcome is one in which
the protective allele has a frameshift insertion that ablates IFN-
l4 production (for SNP rs368234815, the protective allele is
TT rather than -G) (Bibert et al., 2013; Hamming et al., 2013;
Key et al., 2014; O’Brien et al., 2014; Prokunina-Olsson et al.,
2013). It remains unclear why the loss of IFN-l4 confers
improved clinical outcome, but several explanations have been
proposed: (1) a counter-regulatory role for IFN-l4, (2) an IFN re-
fractory state induced by high basal expression of IFN-l4,
(3) stimulation of regulatory T cell responses by IFN-l4, and/or
(4) reduced production of the more antiviral IFN-l3. Because
many of the polymorphisms within the IFNL locus exist in high
linkage disequilibrium, they often segregate as haplotypes.
This has made it difficult to parse out the protective functions
of individual SNPs. For example, many of the protective pheno-
types initially attributed to rs12979860 (C/C allele) might in fact
be caused by the loss of IFN-l4 production as a result of the
highly linked and more recently identified rs368234815 (TT
allele).
There was significant interest in the therapeutic potential of
IFN-l for viral hepatitis (Donnelly et al., 2011; Hayes et al.,
2012), at least before the introduction of direct-acting antiviralagents to treat HCV infection (Alexopoulou and Karayiannis,
2015). Conventional pegylated IFN-a therapy is accompanied
by side effects that hinder compliance. Given themore restricted
expression pattern of IFNLR, and the relatively high amount of
IFNLR expression in hepatocytes, IFN-l could confer many of
the antiviral benefits of IFN-a in the liver with reduced side effects
(Muir et al., 2014). Although direct-acting antiviral agents are
supplanting IFN therapy for HCV infection, the therapeutic ad-
vantages of IFN-l might still have utility against HBV, other viral
infections, or other hepatic conditions.
Although human hepatocytes respond to IFN-l, mouse hepa-
tocytes are less responsive. Instead, cholangiocytes that line the
bile duct reportedly are the principal cells that respond to IFN-l
in the mouse liver (Hermant et al., 2014; Mahlako˜iv et al., 2015).
This observation could explain the apparent lack of an antiviral
activity for IFN-l in mouse models of hepatotropic virus infec-
tion, despite its clear role in human hepatitis (Mordstein et al.,
2008). Because of their IFN-l responsiveness, cholangiocytes
could restrict excretion of hepatotropic viruses into the bile
and thus control viral spread in feces.
IFN-l in the Gastrointestinal Tract
The gastrointestinal tract is a primary site of microbial exposure,
and intestinal epithelial cells form a barrier to pathogenic viruses
and bacteria (Figure 2C). Initial characterization of tissue Ifnlr1
expression in mice demonstrated relatively high expression in
the stomach and intestine (Sommereyns et al., 2008), and subse-
quent studies revealed that epithelial cells are the predominant
IFN-l-responsive cell type in the gastrointestinal tract (Mordstein
et al., 2010b; Pott et al., 2011). IFN-l and IFN-a/b responsive-
ness are compartmentalized within the mouse intestine. IFN-
a/b has a minimal effect on intestinal epithelial cells, whereas
IFN-l has a minimal effect on cells of the lamina propria (Mahla-
ko˜iv et al., 2015; Pott et al., 2011). This differential response
might be explained by the relatively high expression of IFNLR
on intestinal epithelial cells (Mahlako˜iv et al., 2015), as well as
the low expression and apical trafficking of IFNAR on these cells
(Pott et al., 2011). Although IFNLR1 transcripts are expressed in
the human gastrointestinal tract (Sheppard et al., 2003), it re-
mains to be determined whether IFN-l and IFN-a/b responsive-
ness are similarly compartmentalized.
The compartmentalized response to IFN-l in the mouse
gastrointestinal tract most likely explains its activity against
different viral pathogens depending on their cellular tropism.
Rotavirus infects epithelial cells (Lopez and Arias, 2006), reovirus
replicates in both epithelial and non-epithelial cells (Forrest and
Dermody, 2003), and norovirus grows preferentially in myeloid
and B cells but not in epithelial cells (Jones et al., 2014; Karst
et al., 2014; Wobus et al., 2004). Rotavirus infection is controlled
exclusively by IFN-l, and there is no defined role for IFN-a/b
(Angel et al., 1999; Pott et al., 2011). Reovirus is controlled coop-
eratively by IFN-a/b and IFN-l, such that IFN-l limits replication
in epithelial cells, and IFN-a/b restricts infection in non-epithelial
cells (Mahlako˜iv et al., 2015). Norovirus infection and dissemina-
tion are controlled by IFN-a/b and IFN-l, such that IFN-a/b pre-
vents extra-intestinal spread, and IFN-l inhibits the persistent
shedding of virus in feces (Nice et al., 2015; Nice et al., 2013).
The role for IFN-l in norovirus infection is apparent only for
strains that are persistently shed across the intestinal epithelial
barrier into the gut lumen and not for strains causing only acuteImmunity 43, July 21, 2015 ª2015 Elsevier Inc. 19
Figure 2. Antiviral Effects of IFN-l at Barrier Surfaces
(A) IFN-l is a dominant IFN produced after viral infection in the respiratory tract. Respiratory epithelial cells can respond to both IFN-l and IFN-a/b to activate an
antiviral response. Th1 skewing induced by IFN-l reduces the severity of allergic asthma.
(B) The fenestrated endothelium of the liver creates a tissue architecture in which hepatocytes directly contact blood in liver sinusoids. Hepatocytes are the
primary cellular targets for HBV and HCV and are highly responsive to IFN-l. A role for IFN-l in controlling HCV infection is suggested by the association between
HCV clinical outcome and numerous SNPs within the IFNL locus.
(C) IFN-l has a key role in gastrointestinal tract immunity because unlike respiratory epithelial cells, gut epithelial cells do not respond to IFN-a/b and therefore rely
upon IFN-l to activate an antiviral response. The antiviral effects of IFN-l could be especially important for restricting the shedding and transmission of enteric
viruses. Immunity in the gastrointestinal tract is shaped by the bacterial microbiome; the ability of gut microbes to promote viral persistence requires IFN-l
signaling, although the mechanism of this interaction remains unclear.
(D) IFN-l signaling tightens the endothelial junctions of the BBB, which reduces viral neuroinvasion from the circulation. The tightening activity of IFN-l is STAT1
independent, implicating a non-canonical signaling pathway.
(E) Psoriasis and atopic dermatitis are chronic inflammatory skin conditions characterized by breakdown of the epithelial barrier. Compared to lesions from atopic
dermatitis patients, psoriasis lesions exhibit elevated IFN-l production and enhanced expression of ISGs. This might explain why disseminated viral skin in-
fections are common in patients with atopic dermatitis but not psoriasis.
20 Immunity 43, July 21, 2015 ª2015 Elsevier Inc.
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related gastrointestinal viruses reveal unique antiviral roles for
IFN-a/b and IFN-l. In particular, IFN-l selectively prevents viral
shedding into the lumen of the gastrointestinal tract and trans-
mission of fecal-oral viral pathogens.
The trillions of bacteria juxtaposed to the intestinal epithelial
barrier are a source of numerous microbial products that are
sensed by the immune system. Thus, the IFN-mediated antiviral
response in the gastrointestinal tract is modulated by the bacte-
rial microbiome. Indeed, a recent study showed that the bacterial
microbiome promotes persistent norovirus infection in an IFNLR-
dependent manner (Baldridge et al., 2015). Fecal shedding of
norovirus, but not viral entry into Peyer’s patches or extra-intes-
tinal spread, is reduced in mice treated with antibiotics that
deplete the bacterial microbiome. This effect of antibiotics on
norovirus shedding is diminished in Ifnlr1/ mice, but not in
Ifnar1/, Ifngr1/, Tlr4/, Myd88/, or Trif/ mice, which
lack other innate immune signaling components. The specific
requirement for IFNLR in bacterial promotion of norovirus infec-
tion contrasts with that in poliovirus and mouse mammary tumor
virus (MMTV) infections, where bacterial promotion of viral infec-
tion depends on bacterial lipopolysaccharide and TLR4, respec-
tively (Kane et al., 2011; Kuss et al., 2011). However, an addi-
tional role of IFN-l in poliovirus and MMTV infections remains
possible because TLR4 signaling and bacterial infection induce
IFN-l (Bierne et al., 2012; Coccia et al., 2004; Contoli et al.,
2006; Odendall et al., 2014). Further experiments are required
to characterize the intestinal production of and response to
IFN-l in the presence and absence of enteric bacteria. Given
the importance of IFN-l to intestinal immunity in mice, studies
to test for linkage between human IFN-l SNPs and the control
of enteric viral infections appear warranted. The studies in
mice also suggest that IFN-l might have therapeutic applica-
tions for humans with persistent norovirus infection and gastro-
enteritis (Bok and Green, 2012).
The ability of IFN-l to confer antiviral protection at epithelial
barriers is an interesting parallel to another IL-10 family cytokine,
IL-22, which promotes antibacterial immunity at epithelial sur-
faces (Zheng et al., 2008). Similar to IFNLR1, IL22Ra associates
with IL10Rb and is expressed preferentially by epithelial cells
(Wolk et al., 2004). A recent study demonstrated that IL-22
acts synergistically with IFN-l to control rotavirus infection and
prevent intestinal tissue damage in mice (Herna´ndez et al.,
2015). Further work is needed for determining whether IL-22
contributes to the antiviral activity of IFN-l at other epithelial sur-
faces and against other viruses targeting the gastrointestinal
tract.
IFN-l and Chronic Viral Infection
Surprisingly, IFN-l stimulates clearance of persistent norovirus
infection independently of the adaptive immune system (Nice
et al., 2015), suggesting that innate immune responses might
have a greater role in determining viral persistence than previ-
ously appreciated. Because IFNLR is expressed on epithelial
cells, IFN-l could be particularly important for restricting shed-
ding of chronic viral infections. Consistent with this idea, IFN-l
treatment decreases HSV-2 shedding from the vaginal mucosa
in mice (Ank et al., 2006). In humans, SNPs in IFNL3 and IFNL4
have been associated with the ability to clear or control multiple
chronic infections, including HCV, HBV, HCMV, and HSV-1 (Bi-bert et al., 2014; Egli et al., 2014a; Egli et al., 2014c; Griffiths
et al., 2015; Griffiths et al., 2013; Lampertico et al., 2013; Manuel
et al., 2015). Although the mechanisms by which these polymor-
phisms affect IFN-l production and activity remain unclear,
these associations suggest that IFN-l contributes to the control
of chronic viral infections in humans. Restricted IFNLR expres-
sion within themucosal epithelium and other key cell typesmight
allow targeted local antiviral responses that control chronic
infection and shedding without generating a potentially delete-
rious systemic pro-inflammatory response. A greater mecha-
nistic understanding of how human SNPs influence IFN-l
expression or function and the study of IFN-l in additional
models of chronic viral shedding are needed.
IFN-l at the BBB
A recent study with West Nile virus (WNV) demonstrated an
antiviral effect of IFN-l at an unexpected barrier site: the BBB
(Lazear et al., 2015). The BBB protects the CNS from harmful
substances in the periphery, including viruses (Koyuncu et al.,
2013). Ifnlr1/ mice exhibited increased BBB permeability after
WNV infection and sustained higher viral titers in CNS tissues.
Although endothelial cells, including those composing the
BBB, do not express high levels of IFNLR, administration of
exogenous IFN-l tightened the BBB, restricted viral neuroinva-
sion, reduced viral titers in the CNS, and protected mice from le-
thal viral infection (Figure 2D). These observations are consistent
with those of a study demonstrating that IFN-a/b also can exert a
tightening effect on the BBB (Daniels et al., 2014). IFN-l tight-
ening of endothelial monolayers in an in vitro model of the BBB
did not require STAT1 or de novo protein synthesis, implying
that the phenotype occurred via a non-canonical signaling
pathway. Although further experiments are needed for deter-
mining the specific pathway by which it exerts its effects on
BBB integrity, this study suggests that IFN-l might have thera-
peutic activity for pathological conditions or viral infections that
involve BBB breakdown or permeability.
IFN-l Roles in Autoimmunity, Adaptive Immunity,
and Anti-tumor Responses
The most direct consequence of IFN-l signaling is the induction
of ISGs, which can act in a cell-intrinsic manner to inhibit viral
infection (Figure 1). However, IFN-l has immunologic roles
beyond the innate antiviral response. There is increasing evi-
dence that IFN-l shapes the adaptive immune response to viral
infection, alters anti-tumor responses, and affects autoimmunity.
IFN-l and Autoimmunity
Altered expression or activity of components of pathogen
sensing and IFN-induction pathways is associated with autoim-
munity. For example, alterations in the PRR MDA5, signaling
molecule STING, or transcription factor IRF-5 can cause severe
clinical syndromes known as ‘‘type I interferonopathies’’ (Crow,
2015; Rigby and Rehwinkel, 2015). As overlapping stimuli, sen-
sors, and signaling mechanisms induce expression of type III
IFNs, these same alterations might enhance IFN-l production
and contribute to these clinical phenotypes.
Given that it exerted a tightening effect on the BBB, IFN-l
could have a prominent barrier effect in epithelial tissues where
IFNLR expression is higher. In the skin, IFNLR is expressed pre-
dominantly on keratinocytes (Witte et al., 2009). The barrier func-
tion of keratinocytes is important, as evidenced by the pathologyImmunity 43, July 21, 2015 ª2015 Elsevier Inc. 21
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acterized by epithelial cell hyperproliferation, impaired barrier
function, and inflammation (Figure 2E) (Clark, 2013; Leung,
2013; Perera et al., 2012). Patients with atopic dermatitis
commonly develop disseminated bacterial (e.g., Staphylo-
coccus aureus) and viral (e.g., HSV, human papillomavirus, and
molluscum contagiosum poxvirus) infections in the skin (Christo-
phers and Henseler, 1987; Wollenberg et al., 2003). However,
these disseminated infections are not characteristic of psoriasis.
Skin lesions from psoriasis patients exhibit higher amounts of
IFN-l1 and enhanced expression of ISGs than do atopic derma-
titis lesions, and this occurs in the absence of differential expres-
sion of IFN-a/b (Wolk et al., 2013). Although altered epithelial
barrier function is a feature of both psoriasis and atopic derma-
titis, elevated IFN-l production and ISG expression provide anti-
viral protection only in the context of psoriasis.
The factors that cause elevated IFN-l production in psoriasis
are not understood but might result from the Th17-driven
response in psoriatic lesions rather than a Th2-driven response
in atopic dermatitis. Th17 cells are the main source of IFN-l in
psoriasis lesions, and IFN-l inhibits the production of Th2 cyto-
kines, particularly IL-13 (Srinivas et al., 2008; Wolk et al., 2013). A
protective role for IFN-l in psoriasis is also suggested by the link-
age of a SNP in the 30 UTR of IFNLR1 to disease outcome (for
SNP rs4649203, the protective allele is G rather than A), although
a mechanistic basis for this association remains uncertain (Li
et al., 2013; Strange et al., 2010).
A protective role for IFN-l in allergic asthma also has been
proposed (Figure 2A) (Koch and Finotto, 2015). Cells from
asthma patients have impaired IFN-l production after rhinovirus
infection (Contoli et al., 2006). IFN-l downregulates inflamma-
tory Th2 cytokines, including IL-4, IL-5, and IL-13 (Jordan
et al., 2007b; Koltsida et al., 2011; Srinivas et al., 2008), which
contribute to asthma pathogenesis. In amousemodel of asthma,
administration of IFN-l reduced the production of IL-5 and IL-13,
diminished eosinophil infiltration into the lung, and decreased
Th17 cell responses, all of which minimized disease (Koltsida
et al., 2011). The protective activity of IFN-l in this model de-
pended on IL-12 and IFN-g, implicating the Th1-skewing effects
of IFN-l.
In a recent study using amousemodel of autoimmune arthritis,
IFN-l treatment reduced neutrophil recruitment into the joints
and resulted in improved disease outcome (Blazek et al.,
2015). This work identifies neutrophils as IFN-l-responsive cells
and suggests therapeutic applications for IFN-l in treating auto-
immune arthritis and other inflammatory conditions.
Despite their linkage to other autoimmune conditions, human
SNPs near the genes encoding IFN-l (rs8099917 and
rs12979860) or IFNLR1 (rs4649203) did not show an association
with multiple sclerosis (Lopez de Lapuente et al., 2012; Malhotra
et al., 2011). Furthermore, the IFNLR1 allele that is protective for
psoriasis was associated with exacerbated systemic lupus ery-
thematosus (for SNP rs4649203, the protective allele is A rather
than G) (Li et al., 2013), suggesting distinct contributions of IFN-l
signaling to different autoimmune conditions.
IFN-l in Cancer
IFN-a is currently approved as a therapeutic agent for some can-
cers. The primary anti-tumor mechanisms of IFN-a/b are cell-
intrinsic induction of apoptosis and cell-extrinsic stimulation22 Immunity 43, July 21, 2015 ª2015 Elsevier Inc.and priming of immune cells (Booy et al., 2015; Di Trolio et al.,
2015). Given that IFN-l signaling triggers similar downstream
gene expression, but in a restricted subset of IFNLR-bearing
cells, it could serve as a more targeted therapeutic option. In
support of this concept, IFNLR signaling induces apoptosis in
colorectal cancer cells more potently than IFN-a/b or IFN-g (Li
et al., 2008) and inhibits growth and colony formation of several
different tumor cell lines (Sato et al., 2006).
Induction of IFN-l in response to viral infections could also
promote anti-tumor immune responses. IFN-l has been de-
tected in human papillomavirus lesions, and lower levels of
IFN-l expression correlated with progression to cervical cancer
(Cannella et al., 2014). Infection with a vesicular stomatitis virus
strain intended for use as an oncolytic treatment also triggered
IFN-l expression in hematopoietic cells in vitro and enhanced
anti-tumor natural killer (NK) cell responses in vivo (Wongthida
et al., 2010). Loss of IFNLR expression on tumor cells prevented
IFN-l-stimulated expression of stimulatory ligands for the NK
cell receptor NKG2D and associated anti-tumor NK cell re-
sponses (Wongthida et al., 2010).
IFN-l is also present in the tumor microenvironment in the
absence of a viral infection. IFNLR expression on mammary
epithelial cells inversely correlated with tumor growth in a mouse
model of breast cancer (Burkart et al., 2013). IFN-l signaling on
mammary epithelial cells promoted production of the chemokine
CXCL10, which recruits CD4+ T cells into the tumor microenvi-
ronment (Burkart et al., 2013). Tumormodels withmelanoma, co-
lon carcinoma, and fibrosarcoma cells also demonstrated a role
of IFN-l in triggering anti-tumor NK and T cells (Lasfar et al.,
2006; Numasaki et al., 2007; Sato et al., 2006). An increased
anti-tumor immune responsewas apparent evenwhen the tumor
cells themselves lacked the ability to respond to IFN-l (Lasfar
et al., 2006; Numasaki et al., 2007). Recent work has demon-
strated that Ifnlr1/ mice are more susceptible to sarcoma for-
mation induced by the carcinogen methylcholanthrene and
death in transplanted tumor models (either RMA or B16F10 cells)
(Souza-Fonseca-Guimaraes et al., 2015). Furthermore, IFN-l
treatment delayed lethality in the B16F10 adoptive cell transfer
model and reduced sarcoma development in methylcholan-
threne-treated mice (Souza-Fonseca-Guimaraes et al., 2015).
Despite low levels of IFNLR expression, NK cells might respond
directly to IFN-l in vivo, resulting in enhanced IFN-g production
and anti-tumor activity (Souza-Fonseca-Guimaraes et al.,
2015). Because IFN-l can alter tumorigenesis directly and indi-
rectly, it might have utility as an adjunctive anti-cancer therapy.
IFN-l Modulates Adaptive Immunity
Although its innate antiviral effects have been characterized
more extensively, IFN-l also modulates adaptive immunity. Dur-
ing acute LCMV infection with the Armstrong strain, Ifnlr1/
mice had increased expansion of CD4+ and CD8+ T cells and
enhanced T cell responses to LCMV rechallenge (Misumi and
Whitmire, 2014). These data suggest that IFN-l, in contrast to
IFN-a/b, inhibits T cell responses during acute viral infection.
This effect was cell extrinsic given that IFNLR signaling was
not required on the T cells (Misumi and Whitmire, 2014). Howev-
er, IFN-l had a different effect during chronic LCMV infection:
Ifnlr1/ mice infected with LCMV clone 13 had reduced CD8+
T cell expansion and increased weight loss (Misumi and
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fects in the magnitude or quality of antigen-specific CD8+ T cell
responses in the spleen or brain after WNV infection (Lazear
et al., 2015), indicating that virus-specific host interactions might
affect how IFN-l modulates the adaptive immune response.
Additional studies are required to define the role of IFN-l in
adaptive immunity to mucosal infections, where IFNLR is more
abundantly expressed.
Although there are conflicting reports on whether human lym-
phocytes respond directly to IFN-l (Dickensheets et al., 2013;
Gallagher et al., 2010), there is consensus that IFN-l modulates
T cell responses. The addition of IFN-l during stimulation of pe-
ripheral-blood mononuclear cells (PBMCs) with concanavalin A
or during a mixed lymphocyte reaction reduced the production
of Th2 cytokines (IL-4, IL-5, and IL-13) and increased the produc-
tion of IFN-g, suggesting that IFN-l promotes a Th1 response
(Dai et al., 2009; Jordan et al., 2007b; Srinivas et al., 2008).
Consistent with these data, a SNP (rs8099917, with the T/T allele)
in the IFNL3 locus was linked to increased IFN-l3 production
and skewing toward a Th1 response after PBMCs were stimu-
lated with influenza virus (Egli et al., 2014b). Furthermore, admin-
istration of IFN-l as a vaccine adjuvant resulted in reduced
expression of the Th2 cytokine IL-4 by HIV gag-specific T cells
and reduced numbers and activity of regulatory T cells (Morrow
et al., 2009). Collectively, these observations suggest that IFN-l
skews T cell responses toward a Th1 cell bias and away from a
Th2 cell bias.
The humoral immune response might be regulated by IFN-l,
although the net effect is not clear. Increased seroconversion
in response to influenza or measles vaccines correlated with
SNPs in the IFNL3 promoter (the T/T allele for rs8099917 and
the G/G allele for rs10853727) (Egli et al., 2014b; Haralambieva
et al., 2011). The T/T allele of SNP rs8099917 was linked to
increased production of IFN-l and decreased seroconversion
after influenza vaccination (Egli et al., 2014b). In vitro experi-
ments showed reduced antibody production by PBMCs stimu-
lated with influenza virus in the presence of IFN-l and increased
antibody titers in the presence of an IFNLR-blocking peptide
(Egli et al., 2014b). In contrast, a stimulatory effect on humoral
response was observed in an HIV vaccine study comparing
IFN-l and IL-12 as adjuvants: the IFN-l-adjuvanted vaccine re-
sulted in a greater increase in IgG2a responses than did the IL-
12-adjuvanted vaccine (Morrow et al., 2009). However, in the
context of WNV or LCMV infection, antiviral antibody production
was the same between Ifnlr1/ mice and wild-type animals
(Lazear et al., 2015; Misumi and Whitmire, 2014). Thus, the
impact of IFN-l on humoral immunity appears to be context
dependent and requires further evaluation.
More Than Just Viral Infections
Although known for their antiviral effects, IFN-a/b and IFN-l
might function in other microbial infections as well. Whereas
IFN-a/b signaling protects against viral infections, it can be
detrimental in the context of infection by some bacteria (e.g.,
Mycobacterium tuberculosis and Listeria monocytogenes) and
parasites (e.g., Leishmania spp.) (Stifter and Feng, 2015).
IFN-l also is induced by bacterial infection (Bierne et al.,
2012; Cohen and Prince, 2013; Lebreton et al., 2011; Love
et al., 2014; Odendall et al., 2014; Pietila¨ et al., 2010; Travaret al., 2014) and might have consequences during Staphylo-
coccus and Pseudomonas infections: Ifnlr1/ mice sustained
lower bacterial loads and exhibited less pathology without dif-
ferences in inflammatory cell infiltrates (Cohen and Prince,
2013). Further investigation into the role of IFN-l in non-viral in-
fections is warranted. The effects of IFN-l in the context of
helminth infections could be especially interesting given its
ability to downregulate Th2 responses (Jordan et al., 2007b;
Srinivas et al., 2008).
Antagonism of IFN-l
Given the antiviral effects of IFN-l, it is anticipated that some vi-
ruses will have evolved specific evasion strategies. IFN-a/b
antagonist mechanisms have been described for many virus
families (Hoffmann et al., 2015); because some of these target in-
duction or signaling pathways shared between IFN-l and
IFN-a/b, these same evasion strategies most likely limit the ef-
fects of IFN-l as well. Viruses targeting epithelial tissues might
be especially likely to encode specific IFN-l-evasion mecha-
nisms. Yaba-like disease virus (YLDV) is a primate poxvirus
that exclusively infects the skin. Similar to other orthopoxviruses,
YLDV encodes a secreted glycoprotein (Y136) that binds to IFN-
a/b and blocks IFNAR signaling. Unlike orthologs in vaccinia or
variola viruses, Y136 also binds to and inhibits the antiviral ef-
fects of IFN-l (Bandi et al., 2010; Huang et al., 2007). Because
the structure of IFN-l is distinct from that of IFN-a/b (Gad
et al., 2009), it remains uncertain how a single viral evasion pro-
tein targets both IFN-l and IFN-a/b. Because they infect epithe-
lial cells and their large genomes enable them to encode a suite
of immune evasion molecules (Epperson et al., 2012), other pox-
viruses and herpesviruses might have evolved analogous or
unique mechanisms to antagonize IFN-l responses.
IFN-l across Species
The use of Ifnlr1/ mice has provided insight into the role of
IFN-l in antiviral immunity (Hermant and Michiels, 2014; Her-
na´ndez et al., 2015; Lazear et al., 2015; Mahlako˜iv et al.,
2015; Mordstein et al., 2010a; Nice et al., 2015). Nonetheless,
differences in IFN-l between mice and humans should be
considered when one interprets its array of activities. Whereas
humans have three or four functional IFNL genes, mice have
only two (Ifnl2 and Ifnl3), because the IFNL4 genomic region
is absent in mice and mouse Ifnl1 is a pseudogene. Compared
to human studies, mouse studies might underestimate some of
the contributions of IFN-l because they lack IFN-l1. Given that
most IFN-l transcriptional profiling to date has focused on hu-
man cells, studies are needed to characterize IFN-l responses
in mouse cells to inform the interpretation of mouse models of
disease.
The IFN-l family is conserved throughout tetrapod evolution,
as evidenced by synteny and structural similarity among
mammalian, avian, and amphibian IFN-l-encoding genes. In
comparison, fish have genes encoding IFN-a/b but not IFN-l
(Qi et al., 2010). Antiviral effects of avian IFN-l have been docu-
mented (Reuter et al., 2014), and in tadpoles, IFN-l rather than
IFN-a/b dominantly inhibits infection by frog virus 3 (Grayfer
et al., 2015).
In contrast to the preferential epithelial expression pattern of
IFNLR in humans and mice, in the bat Pteropus alecto, IFNLRImmunity 43, July 21, 2015 ª2015 Elsevier Inc. 23
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2011a). Infection of P. alecto splenocytes with the paramyxo-
virus Tioman virus induced the expression of IFN-l1 but not
IFN-a/b (Zhou et al., 2011b). It will be interesting to determine
whether broader tissue responsiveness to IFN-l in bats contrib-
utes to their ability to serve as reservoir hosts for diverse viruses
(Baker et al., 2013). For example, enhanced IFN-l responsive-
ness might enable bats to control viral infections without devel-
oping disease. Alternatively, sustained IFN-l signaling might
impede the activation of more potent antiviral responses and
prevent bats from clearing viral infections.
Although the mouse and rat genomes lack IFNL4, this gene
is conserved in most mammals and displays evidence of pos-
itive selection, implying functional significance (Key et al.,
2014). In some human populations, however, IFNL4 is under-
going pseudogenization with the acquisition of a frameshift
insertion in the IFNL4 open reading frame that ablates IFN-l4
production (Hamming et al., 2013; Prokunina-Olsson et al.,
2013). The frequency of this polymorphism varies, such that
the ancestral (IFN-l4-producing) allele dominates in African
populations, and the pseudogene allele has reached near fixa-
tion in East Asian populations (Key et al., 2014). The selective
pressure driving IFNL4 pseudogenization in humans remains
unknown, but GWASs suggest a strong association between
the pseudogene allele of IFNL4 and improved outcome after
HCV infection (Griffiths et al., 2015; Hamming et al., 2013; Pro-
kunina-Olsson et al., 2013). Because HCV infection is unlikely
to provide sufficient selective pressure to drive this evolu-
tionary process, the loss of IFN-l4 production might be advan-
tageous in the context of other infections or inflammatory
conditions.
Conclusions
Since its discovery in 2003, many groups have identified contri-
butions of IFN-l to antiviral and other immune responses. These
studies have prompted a growing appreciation of the unique fea-
tures that distinguish IFN-l from IFN-a/b, and these features pro-
vide possibilities for more targeted therapeutic intervention. The
ability of IFN-l to provide antiviral protection at specific tissue
sites (e.g., epithelial surfaces) could explain the maintenance
of a system that appears somewhat redundant with the IFN-
a/b response. Epithelial surfaces could require greater innate im-
mune protection because of their constant exposure to
commensal and pathogenic microbes. Constant microbial stim-
ulation at epithelial barriers could require local control without
broadly activating a systemic immune response. Thus, IFN-l
signaling could control frequent or persistent low-level infections
at epithelial barriers, and the more potent and inflammatory sys-
temic IFN-a/b response could be reserved for severe infections.
This compartmentalized tissue responsiveness to IFN-l could
be utilized therapeutically as a means of achieving antiviral
benefit while minimizing systemic side effects associated with
inflammation.
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